Moderna Competitors

Stocks . Brazil . 
Stock . Moderna
M1RN34 Stock  BRL 12.05  0.04  0.33%   
Moderna competes with Novo Nordisk, Vertex Pharmaceuticals, BIONTECH, and BeiGene; as well as few others. The company operates under Healthcare sector and is part of Biotechnology industry. Analyzing Moderna competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Moderna to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Moderna Correlation with its peers.
For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Moderna competition on your existing holdings.
  
Hype
Prediction
LowEstimatedHigh
8.4812.0515.62
Details
Intrinsic
Valuation
LowRealHigh
7.6511.2214.79
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Moderna. Your research has to be compared to or analyzed against Moderna's peers to derive any actionable benefits. When done correctly, Moderna's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Moderna.

Moderna Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Moderna and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Moderna and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Moderna does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
M1RN34
+ 0.61
N1VO34
BIOM3
+ 0.61
M1RN34
A1SN34
+ 0.61
B1NT34
B1GN34
+ 0.34
M1RN34
A1SN34
+ 0.32
N1VO34
B1NT34
+ 0.25
VRTX34
  
High negative correlations   
BIOM3
- 0.76
B1NT34
T1CH34
- 0.52
B1GN34
M1RN34
- 0.49
VRTX34
B1NT34
- 0.38
M1RN34
BIOM3
- 0.36
VRTX34
BIOM3
- 0.35
A1SN34

Risk-Adjusted Indicators

There is a big difference between Moderna Stock performing well and Moderna Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Moderna's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

Moderna Competitive Analysis

The better you understand Moderna competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Moderna's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Moderna's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
M1RN34 N1VO34 VRTX34 B1NT34 B1GN34 T1CH34 A1SN34 BIOM3
 0.33 
 12.05 
Moderna
 18.64 
 64.83 
Novo
 1.29 
 604.58 
Vertex
 1.92 
 43.50 
BIONTECH
 3.34 
 42.30 
BeiGene
 1.31 
 15.44 
Bio
 0.00 
 53.35 
Ascendis
 2.66 
 7.72 
Biomm
Market Volatility
(90 Days Market Risk)
Somewhat reliable
Very steady
Very steady
Very steady
Very steady
Somewhat reliable
Very steady
Somewhat reliable
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Very Weak
Insignificant
Very Weak
Insignificant
Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Low
Low
Low
Quite High
Low
Below Average
Below Average
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Under Valued
Fairly Valued
Under Valued
Over Valued
Fairly Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Hold
Cautious Hold
Strong Hold
Sell
Sell
Hold
Current Ratio
1.24 X
N/A
4.61 X
N/A
N/A
N/A
N/A
3.56 X
Net Asset
24.67 B
194.51 B
18.15 B
15.83 B
8.65 B
2.29 B
1.08 B
369.83 M
Profit Margin
0.55 %
0.31 %
0.37 %
0.56 %
(1.68) %
0.23 %
N/A
(0.99) %
EBITDA
13.54 B
65.39 B
4.29 B
15.13 B
(1.39 B)
413.76 M
(364.64 M)
(53.76 M)
Operating Margin
0.62 %
0.43 %
0.49 %
0.68 %
(1.52) %
0.26 %
(15.89) %
(0.90) %
Current Valuation
387.59 B
1.59 T
372.17 B
165.09 B
93.43 B
73.29 B
34.82 B
554.55 M
Price To Book
4.44 X
3.46 X
6.20 X
2.30 X
2.09 X
7.19 X
0.90 X
3.63 X
Retained Earnings
N/A
N/A
N/A
N/A
N/A
N/A
N/A
(104 M)
Current Asset
N/A
N/A
N/A
N/A
N/A
N/A
N/A
61 M
Beta
1.64
0.33
0.46
0.2
0.72
1.21
0.47
0.43
Number Of Employees
3.7 K
54.39 K
4.8 K
4 K
9 K
3 K
639
148
Shares Outstanding
7.68 B
2.25 B
1.03 B
3.88 B
1.35 B
4.72 B
57.03 M
81.29 M
Cash Flow From Operations
13.62 B
55 B
2.64 B
889.7 M
(1.3 B)
325.27 M
(417.65 M)
(93.78 M)
Annual Yield
N/A
0.01 %
N/A
0.01 %
N/A
0 %
N/A
N/A
Total Debt
599 M
9.65 B
509.8 M
171.6 M
202.11 M
243.41 M
N/A
134.07 M
Return On Equity
0.84
0.72
0.28
0.76
-0.53
0.15
-0.67
-0.77
Z Score
N/A
N/A
N/A
N/A
N/A
N/A
N/A
1.8
Return On Asset
0.35
0.22
0.17
0.43
-0.2
0.0771
-0.27
-0.15
Book Value Per Share
4.65 X
37.10 X
13.53 X
76.45 X
44.84 X
0.38 X
8.08 X
1.65 X
Current Liabilities
N/A
N/A
N/A
N/A
N/A
N/A
N/A
20 M
Total Asset
24.67 B
194.51 B
18.15 B
15.83 B
8.65 B
2.29 B
1.08 B
369.83 M
Debt To Equity
0.09 %
N/A
0.1 %
N/A
N/A
N/A
N/A
1.08 %
Last Dividend Paid
N/A
12.4
N/A
N/A
N/A
0.32
N/A
N/A
Shares Owned By Institutions
N/A
N/A
N/A
N/A
N/A
N/A
N/A
30.21 %
Market Capitalization
349.58 B
1.67 T
403.29 B
184.35 B
134.44 B
60.28 B
34.39 B
434.89 M
Price To Earnings To Growth
N/A
0.25 X
0.42 X
0.01 X
N/A
N/A
N/A
N/A
Price To Earning
N/A
N/A
18.08 X
N/A
N/A
N/A
N/A
(8.47) X
Price To Sales
19.80 X
9.46 X
49.16 X
12.63 X
92.86 X
65.05 X
1,080 X
4.40 X
Net Income
12.2 B
47.76 B
3.32 B
10.29 B
(1.41 B)
272.05 M
(383.58 M)
(80.26 M)
Earnings Per Share
7.47 X
18.22 X
17.03 X
13.87 X
(19.92) X
0.28 X
N/A
(1.19) X
Shares Owned By Insiders
N/A
N/A
N/A
N/A
N/A
N/A
N/A
52.30 %
Revenue
18.47 B
140.8 B
8.93 B
18.98 B
1.18 B
1.11 B
7.78 M
107.09 M
Working Capital
N/A
N/A
N/A
N/A
N/A
N/A
N/A
41 M
Cash And Equivalents
7.99 B
N/A
6.71 B
N/A
N/A
N/A
N/A
30.58 M
Cash Per Share
19.80 X
N/A
6.46 X
N/A
N/A
N/A
N/A
1.36 X
Gross Profit
13.86 B
148.51 B
7.55 B
16.07 B
(447.86 M)
758.09 M
4.25 M
26.93 M
Day Typical Price
12.09
64.21
601.05
42.94
42.3
15.44
53.35
7.64
Accumulation Distribution
0.0325
0.0579
0.0175
0.0386
N/A
N/A
N/A
0.0964
Market Facilitation Index
0.4
3.81
10.58
1.68
N/A
N/A
N/A
0.77
Daily Balance Of Power
0.1
(3.90)
(0.75)
0.4881
(9,223,372,036,855)
9.2 T
0.0
0.2597
Period Momentum Indicator
0.04
(14.85)
(7.92)
0.82
(1.46)
0.2
N/A
0.2
Rate Of Daily Change
1.0
0.81
0.99
1.02
0.97
1.01
1.0
1.03
Day Median Price
12.11
63.9
599.29
42.66
42.3
15.44
53.35
7.61
Price Action Indicator
(0.04)
(6.49)
1.33
1.25
(0.73)
0.1
N/A
0.21
Coefficient Of Variation
(544.02)
(722.75)
(2,922)
1546.39
(13,145)
1655.82
14040.3
(756.35)
Mean Deviation
2.77
2.06
1.48
2.05
1.57
1.6
0.4021
2.18
Jensen Alpha
(0.66)
(0.44)
(0.11)
0.1567
(0.03)
0.2198
(0)
(0.42)
Total Risk Alpha
(0.76)
(0.54)
(0.16)
0.0913
(0.11)
0.1145
(0.04)
(0.49)
Sortino Ratio
N/A
N/A
N/A
0.0539
N/A
0.0538
N/A
N/A
Downside Variance
N/A
N/A
N/A
7.39
N/A
13.81
N/A
N/A
Standard Deviation
3.53
3.21
2.42
2.76
2.78
3.85
1.51
2.97
Kurtosis
0.0254
15.12
13.98
0.8072
5.42
27.97
37.59
1.18
Potential Upside
5.45
3.49
2.93
5.3
3.97
4.48
0.2463
5.34
Treynor Ratio
(3.15)
0.852
(0.10)
0.3127
5.02
2.03
0.0056
(0.45)
Maximum Drawdown
15.77
10.24
19.04
13.89
20.13
30.78
13.57
15.51
Variance
12.45
10.31
5.86
7.63
7.72
14.79
2.29
8.81
Market Risk Adjusted Performance
(3.14)
0.862
(0.09)
0.3227
5.03
2.04
0.0156
(0.44)
Risk Adjusted Performance
(0.14)
(0.10)
(0.02)
0.0584
0.0011
0.0558
0.0104
(0.1)
Skewness
(0.04)
(2.84)
(2.41)
(0.29)
(0.61)
4.2
4.96
0.1579
Semi Deviation
N/A
N/A
N/A
2.6
N/A
1.85
N/A
N/A
Information Ratio
(0.19)
(0.15)
(0.05)
0.053
(0.02)
0.052
(0.01)
(0.14)
Value At Risk
(6.87)
(3.79)
(2.85)
(4.55)
(3.73)
(5.56)
(2.22)
(3.95)
Expected Short fall
N/A
N/A
N/A
(2.36)
N/A
(3.11)
N/A
N/A
Downside Deviation
N/A
N/A
N/A
2.72
N/A
3.72
N/A
N/A
Semi Variance
N/A
N/A
N/A
6.77
N/A
3.41
N/A
N/A

Moderna Competition Performance Charts

Five steps to successful analysis of Moderna Competition

Moderna's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Moderna in relation to its competition. Moderna's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Moderna in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Moderna's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Moderna, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Moderna position

In addition to having Moderna in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Market Neutral Funds Thematic Idea Now

Market Neutral Funds
Market Neutral Funds Theme
Funds or Etfs that invest in both long and short positions of different entities to enhance returns from broad market movements over time. The Market Neutral Funds theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Market Neutral Funds Theme or any other thematic opportunities.
View All  Next Launch

Additional Information and Resources on Investing in Moderna Stock

When determining whether Moderna offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Moderna's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Moderna Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Moderna Stock:
How To Invest In Moderna
Details
Is Moderna Stock a good investment?
Details
What is Moderna's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out Moderna Correlation with its peers.
For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.
You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Altman
Z Score
Details
Intrinsic
Valuation
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine if Moderna is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY